Palestine

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

Written by

admin

in

  • Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine)
  • Demonstrates PCR-corrected cure rate of 97.4% based on estimand method, equating…

Continue Reading


News Source: www.novartis.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

More posts